Meritage Group’s AbbVie ABBV Stock Holding History

Meritage Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-615,007	Closed	-$40.1M	–	18
2017 Q1	$40.1M	Buy	615,007 +299,618	+95%	+$18.8M	1.04%	16
2016 Q4	$19.8M	Buy	+315,389	New	+$19.3M	0.53%	20

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group's ABBV Position: Q2 2017 in Review

Meritage Group sold out of AbbVie (ABBV) in Q2 2017, closing a stake of 615,007 shares — an estimated $40.1M sold.

Meritage Group first reported a position in ABBV in Q4 2016 and held it in 2 quarters. The position peaked at $40.1M in Q1 2017. 1,763 funds tracked by Wall St. Rank hold ABBV as of Q2 2017.

Meritage Group reported no remaining AbbVie position as of Q2 2017 after selling out during the quarter.
Meritage Group sold 615,007 AbbVie shares in Q2 2017, an estimated $40.1M.
Meritage Group first reported a position in AbbVie in Q4 2016 and held it in 2 quarters.
Meritage Group's AbbVie position peaked at $40.1M in Q1 2017.
1,763 funds tracked by Wall St. Rank held AbbVie as of Q2 2017.

Based on Meritage Group's 13F filing for Q2 2017, filed 11 Aug 2017.